Combined Use of a Respiratory Broad Panel Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Adult Patients With Sickle-cell Disease Hospitalized for Acute Chest Syndrome. A Bi-centric, Open, Parallel-group, Randomized Controlled Study

About the study

Many patients with Sickle Cell Disease (SCD) may develop Acute Chest Syndrome (ACS). ACS is usually caused by a Lower respiratory tract infection (LRTI) which may be caused by either a bacterium or a virus. Antibiotics are usually used for 7 to 10 days with no microbiological workup.

The hypothesize of the study is that the identification of the microorganisms might lead to a reduction of antibiotics exposure and a better care of the patients.

We speculate that an early pathogen-directed strategy (respiratory broad panel multiplex PCR and early antibiotics interruption based on the PCT values decrease) might reduce the antibiotics exposure in SCD patients with ACS who are hospitalized and for whom an antibiotic treatment is indicated, as compared with usual care

Study point of contact

Guillaume VOIRIOT, MD
01 56 01 65 74
01 56 01 65 74


1 France site


> 18 Years


Not Applicable

Study type






participation requirements

Age ≥ 18 years
Sickle Cell Disease patients with ACS with an antibiotic therapy indication
Signed and informed consent
Affiliated with social security

participation restrictions

Documented extra-pulmonary bacterial infection at the time of inclusion;

Patients who received antibiotics for more than 24 hours before the diagnosis of ACS (during the primary hospitalization)
Known severe immunosuppression (AIDS, neutropenia (<1000 PNN), hematology, solid tumor under chemotherapy, transplanted organ); long-term treatment with hydroxy-carbamide is not considered Pregnant or lactating women; Person deprived of liberty or under legal protection; Participation in another interventional study of type Jardé 1


  • Paris, France, Service de Réanimation et USC médico-chirurgicale, 75020 [Recruiting]
Last updated 2021-11-08